烟曲霉致敏与高危支气管扩张症相关
这项国际多中心研究前瞻性纳入277例支气管扩张症患者,使用含11种粗制及24种重组真菌变应原的扩展面板评估致敏。结果显示,对重组烟曲霉变应原12、15、17的致敏与重症(住院)急性加重相关,尤其在基线急性加重频率低的患者中;亚洲致敏患者临床结局最差。
要点
- 对rAsp f 12、15、17致敏与支气管扩张症重症(住院)急性加重相关。
- 基线急性加重低风险者若致敏,疾病更重且支气管扩张症-COPD重叠更多。
- 亚洲rAsp f 12、15、17致敏患者症状、肺功能及疾病严重度结局最差。
核心结论
- 烟曲霉致敏,尤其对rAsp f 12、15、17,是支气管扩张症中具有临床意义且可能可治疗的特征。
- 该发现在基线急性加重频率较低者和亚洲人群中相关性最高。
研究设计与样本
- 国际多中心评估,覆盖4国6个三级中心,前瞻性招募277例支气管扩张症患者。
- 使用含11种粗制及24种重组真菌变应原(共35种变应原、9695次单项检测)的扩展面板评估致敏。
主要发现
- 对rAsp f 12、15、17的可测反应与重症(住院)急性加重相关,尤其在基线急性加重低者中。
- 致敏的低风险个体较非致敏低风险个体疾病严重度更高、支气管扩张症-COPD重叠更多,该关系在高基线急性加重者中不存在。
- 对相同变应原的多重致敏进一步增加重症(住院)急性加重风险。
- 亚洲rAsp f 12、15、17致敏患者症状更多、肺功能更差、疾病更严重。
关键数值与推荐
- 基线急性加重低定义为研究招募前12个月内<3次,高定义为≥3次。
临床怎么用
- 对支气管扩张症患者,尤其基线急性加重少且为亚洲人群者,可考虑评估烟曲霉致敏。
- 检出rAsp f 12、15、17致敏可能提示重症急性加重高风险,需加强监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fungal sensitization is an increasingly recognized endophenotype in chronic respiratory disease; however, its role in bronchiectasis remains poorly defined. This study aimed to provide the most comprehensive evaluation to date of fungal sensitization and its clinical relevance in bronchiectasis using an expanded panel of crude and recombinant fungal allergens. RESEARCH QUESTION: What are the prevalence and clinical implications of fungal sensitization in bronchiectasis? STUDY DESIGN AND METHODS: An international, multicenter evaluation of fungal sensitization was conducted across 6 tertiary centers in 4 countries (Singapore, Malaysia, the United Kingdom, and Italy), prospectively recruiting 277 individuals with bronchiectasis. Using a comprehensive, expanded allergen panel including 11 crude and 24 recombinant fungal allergens (total of 35 allergens and 9,695 individual assays), sensitization responses were assessed in relation to clinical characteristics, exacerbation frequency, and geographic origin. Low baseline exacerbations were defined as < 3 and high baseline exacerbations as ≥ 3 in the preceding 12 months of study recruitment. RESULTS: Our results showed that sensitization to recombinant Aspergillus fumigatus (rAsp f) was linked to bronchiectasis severity. Measurable responses to rAsp f allergens 12, 15, and 17 were associated with severe (hospitalized) exacerbations, particularly in those with low baseline exacerbations (low risk). "Sensitized" low-risk individuals exhibited significantly greater disease severity and higher occurrence of bronchiectasis-COPD overlap compared with nonsensitized, low-risk individuals, a relationship absent in those with high baseline exacerbations. Polysensitization to the same allergens conferred further additional risks of severe (hospitalized) exacerbations. Notably, Asian patients sensitized to rAsp f allergens 12, 15, and 17 exhibited the poorest clinical outcomes with increased symptoms, poorer lung function, and severe disease. INTERPRETATION: This study shows that A fumigatus sensitization, particularly to rAsp f allergens 12, 15, and 17, is a clinically significant and potentially treatable trait in bronchiectasis. This finding is of highest relevance in individuals with lower baseline exacerbation frequency and of Asian descent.
引用
- Tiew, Narayana, Jaggi, et al. Aspergillus fumigatus Sensitization Is Associated With High-Risk Bronchiectasis. Chest. 2025. PMID: 41386457. doi:10.1016/j.chest.2025.12.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。